Zanidatamab not checked
Jazz Pharmaceuticals · ZW25 · JZP598
FollowEvery change as it happens, and a Monday email
Trials
11 active
16 in total · 12 in the EU
What this is
- How it works
- Blocks HER2, a growth signal on some breast and stomach cancer cells.Bispecific HER2-directed Antibody FDA class
- Tested for
- Breast Cancer (2 trials), Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma, Metastatic HER2-positive Breast Cancer, Biliary Tract Cancer, Gastric Cancer, Esophageal Cancer and 10 more
- Main trialPhase 3
- “This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).”In the company’s words, NCT05152147 on ClinicalTrials.gov
- Other names
- ZW25 · JZP598 · ZIIHERA
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up4
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
- 29 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 28 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 1 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Jul 2026 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | |
| Phase 3Recruiting | 28 Apr 2028 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | |
| Phase 3Recruiting | 1 Dec 2028 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | |
| Phase 2Recruiting | 31 Dec 2026 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | |
| Phase 2Recruiting | 29 Dec 2027 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | |
| Phase 2Completed | 28 Apr 2023 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant | |
| Phase 2Completed | 28 Jul 2023 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | |
| Phase 2Completed | 30 Aug 2025 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | |
| Phase 1/2Completed | 29 Aug 2025 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | |
| Phase 1Completed | 31 Oct 2024 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | |
| Phase 3Authorised | not given | SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial | |
| Phase 1/2Authorised | not given | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC) | |
| Phase 2Authorised | not given | AcSé HER2_Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers | |
| Phase 2Authorised | not given | ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients | |
| Phase 1/2Authorised | not given | Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial | |
| Phase 1/2Authorised | not given | PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026